S-pantoprazole 10mg Phase III Clinical Study

Inclusion Criteria:

• Adults between the ages of 19 and 75 inclusive

• Patient with a history of heartburn or acid regurgitation for at least 3 months.

• Those with episodes of heartburn for 2 days or more during the last 7 days prior tobaseline

• Patients negative for erosive esophagitis confirmed by esophagogastroduodenoscopy(EGD)performed within 7 days of screening

• Capable of providing written informed consent, willing and able to a comply with allprocedures of the study

Exclusion Criteria:

• History of endoscopic erosive esophagitis(EE) at screening EGD.

• Historical evidence of the following disease/conditions : symptom of Irritable bowelsyndrome

• More tha 3cm endoscopic Barrett's esophagus or significant dysplastic changes in theesophagus

• Proton Pump Inhibitor(PPI) within 4 weeks prior to the baseline visit

• H2-receptor antagonist, sucralfate, prokinetics, Non Steroidal AntiinflammatoryDrugs(NSAIDs) (except low dose aspirin) during the 2 weeks prior to the screening

• Historical evidence of the following disease/conditions during 3 months:Zollinger-Ellison syndrome, the primary esophageal motility disorders achalasia,esophageal stricture, pancreatitis, gastric ulcer, evidence of upper G.I. malignancy,pancreatitis, malabsorption, severe cardiovascular or pulmonary disease, severe liverdisease, severe renal disease, cerebral vascular disease,

• Known hypersensitivity to any component of drug

• pregnancy or lactation (F only)